Share-based Payment Arrangement, Expense of Spyre Therapeutics, Inc. from 31 Mar 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Spyre Therapeutics, Inc. quarterly Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2015 to 30 Sep 2025.
  • Spyre Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $9,566,000, a 27% decline year-over-year.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)

Spyre Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $9,566,000 -$3,534,000 -27% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $9,378,000 +$696,000 +8% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $8,859,000 -$4,976,000 -36% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q3 2024 $13,100,000 +$8,315,000 +174% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $8,682,000 +$6,771,000 +354% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $13,835,000 +$12,126,000 +710% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q3 2023 $4,785,000 +$3,220,000 +206% 01 Jul 2023 30 Sep 2023 10-Q/A 18 Nov 2024 2024 Q3
Q2 2023 $1,911,000 -$107,000 -5.3% 01 Apr 2023 30 Jun 2023 10-Q/A 18 Nov 2024 2024 Q2
Q1 2023 $1,709,000 01 Jan 2023 31 Mar 2023 10-Q/A 18 Nov 2024 2024 Q1
Q3 2022 $1,565,000 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $2,018,000 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2016 $140,000 +$102,000 +268% 01 Jan 2016 31 Mar 2016 10-Q 19 May 2016 2016 Q1
Q1 2015 $38,000 01 Jan 2015 31 Mar 2015 10-Q 19 May 2016 2016 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.